PENSACOLA, FL, May 15, 2025 - ActiGraph, a leading provider of wearable technology and scientific services for clinical drug development and academic research, announced a new strategic partnership with ZEPHYRx, a leading provider of decentralized respiratory solutions for clinical research. Researchers can now take advantage of a robust digital health solution to collect high-quality, real-world data of behavior and respiratory function.
The ZEPHYRx Respiratory Platform offers solutions for both on-site and at-home testing with endpoints including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), slow vital capacity (SVC), peak flow, and fractional exhaled nitric oxide (FeNO). Data is captured and transmitted in real-time, and accessible through the ActiGraph Connect platform. This integrated system empowers clinicians to efficiently screen participants on-site and remotely capture respiratory data using FDA-cleared devices that deliver data quality equivalent to traditional in-lab equipment.
ActiGraph’s AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. This strategic partnership expands digital measurements available for clinical trials to now include the crucial data element of respiratory function. In indications such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and amyotrophic lateral sclerosis (ALS), more frequent, real-world measures of physical function, sleep, and respiratory function can provide a comprehensive view of patient functioning. These more sensitive outcome assessments allow for a robust assessment of treatment efficacy, accelerating development of new treatments.
“The industry has seen significant strides in the application of digital measures in regulated clinical trials, particularly in respiratory diseases,” said Christine Guo, Chief Scientific Officer at ActiGraph. “We’re excited to take the next step with this partnership and offer a combined solution for clinical researchers to capture continuous, objective data of patient functioning across key domains of activity, sleep, and respiratory function.”
"We're thrilled to launch this solution to customers," stated Michael DiCesare, ZEPHYRx President. "This partnership will streamline clinical trial execution by integrating ZEPHYRx and ActiGraph endpoints into a single, centralized platform. This will make it easier for researchers to analyze and interpret the data, improve workflow efficiencies, reduce the burden of data collection on clinical trial sites, and eliminate the need for manual data entry."
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We empower biopharma companies to unleash the potential of big data and AI with a device-inclusive digital trial platform backed by proven operational, scientific, and regulatory expertise. Used in nearly 250 industry-sponsored clinical trials and appearing in over 25K published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.
About ZEPHYRx
ZEPHYRx is a leading provider of cloud-based, decentralized respiratory monitoring solutions for clinical research. Our solutions enable pharmaceutical companies to capture respiratory data at any point in time, expanding participant reach, increasing data volume, and streamlining data collection. ZEPHYRx is committed to delivering a seamless experience to our customers and their participants. Over 50,000 patients worldwide utilize the ZEPHYRx Home solution for remote respiratory monitoring.
Visit our Therapeutic Expertise page - Solutions for Respiratory Research - to learn more about ActiGraph's digital health solutions for respiratory disease clinical trials.
